A review on newly approved PARP inhibitors: Talazoparib and Olaparib

This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024.

Podrobná bibliografie
Hlavní autor:	Karim, Azrin
Další autoři:	Islam, Farzana
Médium:	Project report
Jazyk:	English
Vydáno:	Brac University 2024
Témata:	PARP inhibitors Olaparib Talazoparib DNA damage repair DDR signaling pathway Homologous recombination repair Prostate cancer Ovarian cancer Metastatic breast cancer BRCA mutations Cancer > Treatment > Genetic aspects. DNA repair. NAD-ADP-ribosyltransferase > Inhibitors > Therapeutic use. Antineoplastic agents.
On-line přístup:	http://hdl.handle.net/10361/24372

http://hdl.handle.net/10361/24372

Podobné jednotky